NCT02389985View on ClinicalTrials.gov

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

June 4, 2018

Study Completion Date

October 18, 2018

Conditions
Ovarian Cancer
Interventions
DRUG

CRLX101

DRUG

Paclitaxel

Trial Locations (7)

19107

Thomas Jefferson University, Philadelphia

22901

University of Virginia Health System, Charlottesville

43210

The Ohio State University, Columbus

63110

Washington University, St Louis

73104

University of Oklahoma / Stephenson Cancer Center, Oklahoma City

02114

Massachusetts General Hospital, Boston

02095

Women & Infants Hospital of Rhode Island, Providence

Sponsors
All Listed Sponsors
lead

NewLink Genetics Corporation

INDUSTRY

NCT02389985 - A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter